“…Dermal bioavailability cannot be reliably estimated from IVPT samples, as factors such as drug clearance from tissue into systemic circulation (Ibrahim, Nitsche, & Kasting, 2012; Kapoor, Milewski, Mitra, & Kasting, 2016) and skin metabolism (Manevski et al., 2015; Oesch, Fabian, Oesch‐Bartlomowicz, Werner, & Landsiedel, 2007; Svensson, 2009) may not be easily determined or mathematically modeled. Use of dermal open‐flow microperfusion (dOFM), with the measurement of drug levels in the dermal interstitial fluid, has been reported as a suitable option for assessment of dermal bioavailability (Bodenlenz, Dragatin, et al., 2016; Bodenlenz, Tiffner, et al., 2017); dermal microdialysis has also been used for such a purpose (Erdo, Hashimoto, Karvaly, Nakamichi, & Kato, 2016; Holmgaard et al., 2012; see Current Protocols article; Voelkner, Voelkner, & Derendorf, 2019).…”